[{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Amgen Inc"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Amgen Inc"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Galderma"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Galderma"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A Socio Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Dong-A Socio Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Dong-A Socio Holdings"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Yoshindo","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Yoshindo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Yoshindo \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Yoshindo \/ Biocon"}]

Find Dermatology Drugs in Phase III Clinical Development in JAPAN

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : KHK4083 (rocatinlimab) is an anti-OX40 mAb that inhibits and reduces the number of OX40+ pathogenic T cells responsible for driving systemic and local atopic dermatitis inflammatory responses.

                          Product Name : KHK4083

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 25, 2024

                          Lead Product(s) : Rocatinlimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : CD14152 (nemolizumab) is an anti-IL-31 receptor antibody under study for prurigo nodularis and moderate to severe atopic dermatitis.

                          Product Name : CD14152

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 15, 2024

                          Lead Product(s) : Nemolizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Galderma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : AMG451 (rocatinlimab) an investigational, is a potential first-in-class, anti-OX40 monoclonal antibody that inhibits and reduces the number of OX40+ pathogenic T cells responsible for driving systemic and local atopic dermatitis inflammatory responses.

                          Product Name : KHK4083

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 17, 2023

                          Lead Product(s) : Rocatinlimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : CD14152 (nemolizumab) is a human mAb that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling. It is being investigated for moderate-to-severe atopic dermatitis.

                          Product Name : CD14152

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 14, 2023

                          Lead Product(s) : Nemolizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Ustekinumab, a biosimilar of Stelara, is a monoclonal antibody used to treat several autoimmune conditions and Denosumab, a biosimilar referencing Prolia®, is a monoclonal antibody for the treatment of osteoporosis.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          October 17, 2022

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Biocon

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Patients treated with CD14152 (nemolizumab) monotherapy (without background topical corticosteroids or topical calcineurin inhibitors) showed clinically and statistically significant improvement in both primary endpoints compared to placebo after 16 week...

                          Product Name : CD14152

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 22, 2022

                          Lead Product(s) : Nemolizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Galderma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the terms of the agreement, Intas was granted the exclusive license rights to market DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.

                          Product Name : DMB-3115

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          July 21, 2021

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Intas Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab.

                          Product Name : DMB-3115

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 21, 2021

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Dong-A Socio Holdings

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Difamilast is a topical atopic dermatitis drug candidate discovered by Otsuka that has phosphodiesterase 4 (PDE4) inhibitory activity.

                          Product Name : Moizerto

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 28, 2020

                          Lead Product(s) : Difamilast

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Medimetriks Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Nemolizumab is an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody created by Chugai.

                          Product Name : CD14152

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 07, 2020

                          Lead Product(s) : Nemolizumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank